Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M. Kirkwood, Georgina V. Long, Michele Del Vecchio et al.|Nature Medicine|2023Cited by 208
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patientsJonathan S. Zager, Pedram Gerami, Sarah Estrada et al.|BMC Cancer|2018Cited by 142
Guidance of Sentinel Lymph Node Biopsy Decisions In Patients With T1–T2 Melanoma Using Gene Expression ProfilingJohn T. Vetto, Martin D. Fleming, Eddy C. Hsueh et al.|Future Oncology|2019Cited by 84
Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)Georgina V. Long, John M. Kirkwood, Michele Del Vecchio et al.|SKIN The Journal of Cutaneous Medicine|2023Cited by 25
MCL1 nuclear translocation induces chemoresistance in colorectal carcinomaDechen Fu, Brian Gastman|Cell Death and Disease|2022Cited by 24